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Abstract Receptor activator of NF-kB ligand (RANKL) and
osteoprotegerin (OPG) play key roles in the pathogenesis of
glucocorticoid-induced osteoporosis (GIO). The aim of our
study was to determine whether the cumulative glucocorticoid
dose (CGCS) in children with idiopathic nephrotic syndrome
(INS) has any effect on the concentration of serum RANKL
and OPG and the RANKL/OPG ratio. The study population
consisted of 90 children with INS, aged 3–20 years, who were
treated with GCS. These children were divided into two
groups according to the CGCS: low (L) <1 g/kg body weight
(BW) and high (H) ≥1 g/kg BW, respectively. The control
group (C) consisted of 70 healthy children. RANKL
concentration was observed to be significantly higher and
OPG significantly lower in INS children than in the reference
group: 0.21 (range 0.01–1.36) versus 0.15 (0–1.42) pmol/
l (p<0.05), respectively, and 3.76 (1.01–7.25) versus 3.92
(2.39–10.23) pmol/l (p<0.05), respectively. The RANKL/
OPG ratio was significantly higher in INS children (p<0.01).
The concentration of RANKL, similar to the RANKL/OPG
ratio, was significantly higher in Group H children than in
Group L children: 0.46 (0.02–1.36 ) versus 0.19 (0.01–1.25)
(p<0.01) and 0.14 (0.01–0.71) versus 0.05 (0.002–0.37)
(p<0.01), respectively. The concentration of OPG was
similar in both groups. There was a positive correlation
between CGCS and the concentration of sRANKL as well as
the RANKL/OPG ratio (in both cases r=0.33, p<0.05).
Based on these results, we suggest that long-term exposure
to GCS results in a dose-dependent increase in serum
RANKL concentration and the RANKL/OPG ratio, but not
in the level of serum OPG.
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Introduction
Glucocorticoid-induced osteoporosis (GIOP) was described
for the first time in the early part of the last century by
Cushing, who noticed that patients with endogenous
hypercortisolism were relatively more susceptible than
healthy individuals to bone fracture [1]. However, the
relation between exposure to exogenous glucocorticoids
(GCS) and skeletal disturbances was the subject of heated
discussion for many years. At the present time, GIOP is
considered to be one of the most serious complications of
the pharmacological use of GCS.
Studies in adults have shown that GCS cause rapid and
dose-dependent bone loss [2]. During childhood and
adolescence, skeletal changes result in sex- and maturation-
specific increases in bone dimensions and density. Children
therefore seem to be predisposed to the effects of GCS on
bone formation, leading to possible compromises in peak
bone mass. Decreased bone mineral density (BMD) has
already been described in many of the different pediatric
disorders requiring therapy with GCS, including juvenile
rheumatoid arthritis, inflammatory bowel disease, and
systemic lupus erythematosus [3]. However, the data that
have been published on BMD in children with nephrotic
syndrome (NS) who have been treated with GCS are
equivocal. Some researchers consider that, in contrast to
other medical conditions requiring long-term GCS therapy,
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A. Wasilewska (*) :A. Rybi-Szuminska :W. Zoch-Zwierz
Department of Paediatrics and Nephrology,




Pediatr Nephrol (2010) 25:2067–2075
DOI 10.1007/s00467-010-1583-1
(INS) is stable because the symptoms remit soon after the
initiation of GCS treatment and the time of exposure to GCS
is relatively short [4].
Dual-energy X-ray absorptiometry (DXA) is the most
widely applied method for evaluating bone mineral content
(BMC) and BMD in patients of all ages, but its use in
pediatric patients poses a problem in terms of technical
aspects. A second issue is that height-, gender-, and age-
adjusted normative data are available for the proper
interpretation of results in children with normal glomerular
filtration rate (GFR), but these should not be applied to
children with chronic kidney disease who standardly show
growth retardation and hormonal disturbances. Consequently,
new, easy-to-use markers are necessary.
In 1997, Simonet et al. [5] reported a novel set of
proteins in the tumor necrosis factor (TNF)/TNF receptor
families that were required for the control of bone
remodeling. These receptors, namely, receptor activator
for nuclear factor kappa B (RANK), osteoprotegerin
(OPG), and the RANK ligand (RANKL), were identified
as forming a critical molecular triad that controled bone
remodeling. Subsequent study confirmed that the balance
between the two peptides produced by osteoblasts, OPG
and RANKL, is critical for the bone resorption process [6].
The binding of RANKL to its receptor (RANK) induces
differentiation, activation, and the prevention of osteoclast
apoptosis, leading to enhanced bone resorption and bone
loss [7]. The effects of RANKL can be neutralized by its
decoy receptor OPG, which is an inhibitor of osteoclastic
bone resorption [8]. GCS disturb the function of osteoblasts
and, as a result, they suppress bone formation by decreasing
the number of cells of osteoblastic lineage and inhibiting
their differentiation [9]. In contrast, GCS stimulate the
differentiation and function of osteoclasts, which are cells
derived from the monocyte/macrophage family, differenti-
ating under the control of two cytokines: macrophage
colony-stimulating factor (M-CSF) and receptor activator of
NF-κB ligand (RANKL) [10]. GCS increase the expression
of M-CSF and RANKL and decrease the expression of
RANKL soluble decoy receptor-OPG produced by the
osteoblasts [11]. Consequently, OPG blocks the binding
between RANKL and RANK, thereby playing the role of
the major inhibitor of osteoporosis. The RANKL/OPG ratio
seems to be the key mechanism in the pathogenesis of
GIOP [10].
Few clinical reports have been published on the role of
serum RANKL and OPG levels in the diagnosis of
glucocorticoid-induced osteoporosis. Oelzner et al. [12]
demonstrated that high serum levels of RANKL were
associated with osteoporosis in patients with rheumatoid
arthritis, but that influences of age and gender must also be
considered. Turk et al. [13] found that free sRANKL and
OPG showed a highly inverse relationship in patients with
reduced bone density in the course of Crohn disease but not
in those with healthy skeleton. There have been no
published reports on the role of the RANKL–OPG system
in the diagnosis of GC-induced reduction in BMD in
nephrotic children.
The study reported here is a retrospective study in which
we investigated whether cumulative glucocorticoid dose
(CGCS) in children with INS has any influence on the
concentration of RANKL and OPG and on the RANKL/
OPG ratio.
Materials and methods
The study cohort consisted of 90 children and adolescents
(males 51, females 39), aged 3–20 years, who had been
diagnosed with INS, according to the definition of the
International Society of Kidney Disease in Children [14],
and who had been treated by or had consulted the
Department of Pediatrics and Nephrology and followed up
for 7 years. Inclusion criteria were age 3–20 years, normal
GFR (>90 ml/min/1.73 m2), absence of clinical and
laboratory findings of a systemic disease, ≥6-months
interval since NS diagnosis, a history of systemic GCS
therapy for NS, and remission of NS at the time of
examination.
The children were divided to two groups according to
CGCS, namely, a low [Group L; <1 g/kg body weight
(BW)] and high (Group H; ≥1 g/kg BW) CGCS group and
according to GCS treatment at the time of the study: GCS
(+) and GCS (−).
The control group consisted of 70 healthy, age- and
sex-matched children and adolescents diagnosed in our
Department to have miction disturbances, who were not
on medications [15]. Participants were ineligible if they
had a height or body mass index (BMI) below the third
percentile for age and sex or a history of illnesses or
medications that might affect growth, nutritional status,
pubertal development, or bone accrual. The distributions
of age, sex, height, and BMI did not differ across the
reference groups contributing data for each measurement.
All of the children with INS were treated with the
standard initial therapy, consisting of daily prednisone
60 mg/m2 body surface area for 4 weeks, followed by
40 mg/m2 on alternate days for 2 weeks, and then with
various tapering regimens on alternate days. Relapses were
treated with daily prednisone 60 mg/m2 until remission was
achieved, and then with the standard initial therapy just
described. Based on a survey of the medical historys, more
than 60% of the children had required alternative therapy:
cyclosporine A (CSA) in 33/90 (36%) of patients, cyclo-
phosphamide in 35/90 (39%) patients, chlorambucil in 5/90
(6%) patients, and azathioprin in 2/90 (2%) patients. At the
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moment of the examination, 49 (54%) patients were not
receiving any drug, and 41 (46%) were receiving predni-
sone at a dose ranging from 0.1 to 2 mg/kg BW/24 h.
The medical charts were reviewed for date of diagnosis
of NS, prior therapies, and current medications. Patients
and their parents were interviewed at the study visit to
confirm current medications and the date of the last dose of
GCS therapy.
The protocol was approved by the Bioethics Committee
of the Medical University of Białystok in accordance with
the Declaration of Helsinki.
Urine and blood samples were drawn from all patients and
children in the control group to measure serum RANKL,
OPG, creatinine, albumin, and cholesterol concentrations. All
samples were taken after 12-h of night fasting. Urinalysis was
performed to assess protein and creatinine level and to
determine the protein/creatinine ratio in the morning sample.
The glomerular filtration rate (ml/min/1.73 m2) was estimated
by the Schwartz formula.
A careful clinical history and physical examination were
performed in all children. Height, weight, and BMI were
expressed as centile for age, with reference to published
standards [16]. The stage of pubertal development was
determined using a validated self-assessment questionnaire
and classified according to the method of Tanner.
Serum samples were frozen at −80°C and determined
after sufficient samples had been collected for testing using
one kit, usually after 12–18 months.
Both OPG and RANKL serum concentrations were
determined using an enzyme-linked immunosorbent assay
(ELISA) method according to the instructions given by the
manufacturer (Biomedica Medizinprodukte GMBH,
Vienna, Austria). The detection limit of OPG and RANKL
was 0.14 and 0.02 pmol/l, respectively. The intra- and inter-
assay coefficients of variation (CV) for both markers were:
<10 and <10%, respectively.
Bone mineral content (g) and BMD (g/cm2) in the total
body and lumbar spine were measured by DXA (DPX-L,
ver. 1.3z GE-Lunar Radiation Corp., Madison, WI). The
CV was 1.1% based on repeated scans in 32 pediatric
subjects. The normative data published by Płudowski et al.
[17] in healthy Polish children were used to analyze the
bone DXA results.
Statistical methods
The data were analyzed using the Statistica ver. 8.0 package
(StatSoft, Tulsa, OK). The adequacy of the parameters to
normal distribution was tested using the Shapiro–Wilk test.
Student’s t test was used to compare independent data of
normal distribution, applying the Mann–Whitney U test
when the variables did not follow a normal distribution.
The data with skewed distribution were log-transformed
before starting the statistical tests. Correlations between
clinical and laboratory parameters were tested by Spearman
correlation coefficients. Logistic regression was used to
determine odds ratios (OR) with 95% confidence intervals
(CI) for the effects of each predictor variable on the
outcomes (increased serum RANKL level and RANKL/
OPG ratio or decreased OPG level). The multivariate
logistic regression model yielded an OR and 95% CI for
each factor in the model. All p values are two sided, with
p<0.05 considered to be statistically significant.
Results
The anthropometric and biochemical characteristics of the
study subjects with INS and the reference group are
summarized in Table 1. The age in both groups was similar,
but the proportion of males was significantly greater among
the INS children, which is consistent with the demograph-
ics of childhood INS. Pubertal maturation, assessed by
Tanner stage, was not significantly delayed in the NS
children compared with controls. We found significantly
lower height Z-scores, greater BMI Z-scores, and a greater
prevalence of obesity and short stature in the INS group, as
a result of chronic GCS treatment. All INS children were in
remission of NS syndrome. The serum creatinine and
albumin levels did not differ between the INS children
and the controls.
In INS children, serum level of RANKL was increased
and the level of OPG was decreased in comparison to the
reference group (p<0.05). The RANKL/OPG ratio was also
statistically significant different between the two groups
(p<0.01); however, as the levels of RANKL and OPG
differed between the groups, the statistically significant
difference in their ratio is not independent.
Table 2 shows the disease characteristics of patients with
INS according to CGCS (Group H and L, respectively).
The age at diagnosis of NS in the children of both groups
was comparable (p>0.05), but the interval since diagnosis
was significantly longer in Group H children (p<0.01).
Similarly, the number of relapses was almost threefold
higher in Group H children. At the time of the study visit,
34% of Group L children and 60% of Group H children
were taking oral GCS therapy. The cumulative dose of
prednisone (in g/kg BW) was fivefold higher in Group H
children than in Group L children (p<0.01).
We then analyzed the differences in sRANKL concen-
trations and in the RANKL/OPG ratio between Group H and
L children. The concentration of RANKL was significantly
higher in the group of children treated with a high dose of
CGCS (Group H) than in the group of children with a low
exposure to GCS (Group L): 0.46 (range: 0.02–1.36) versus
0.19 (0.01–1.25) pmol/l (p<0.01). The concentrations of
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OPG (Group H: median 3.72, range 1.00–7.24; Group L:
3.77, 2.19–6.34) were similar in both groups. The RANKL/
OPG ratio was almost threefold higher in Group H children
than in Group L children: 0.14 (0.01–0.71) versus 0.05
(0.002–0.37), respectively (p<0.01).
The serum levels of RANKL and OPG and the RANKL/
OPG ratio were compared between children who were
being treated with GCS at the time of their examination
[GCS (+) group] and those who had not received any
treatment [GCS (−) group] (Fig. 1). Children being
treated with GCS had a statistically significant higher
serum concentration of RANKL (median 0.37 pmol/l,
range 0.05–1.35 pmol/l) than those in the GCS (−) group
(0.18 pmol/l, 0.01–0.85 pmol/l) (p<0.05). Similar results
were shown for the RANKL/OPG ratio. The serum level
of OPG in the GCS (+) group was significantly lower
Variable Nephrotic syndrome (n=90) Controls (n=70) p
Age (years) 10.60±5.52 9.10±4.49 NS
10 (3–19) 9 (2.5–18.0)
Sex (male/female) (% male) 51/39 (56%) 34/36 (49%) NS
Tanner stage, n for each stage Tanner stage 1: 46 (51.1%) 1–45 (64.29%) NS
2: 12 (13.3%) 2–9 (12.86%)
3: 7 (7.7%) 3–5 (7.14%)
4: 10 (11.1%) 4–5 (7.14%)
5: 15 (16.67%) 5–6 (8.57%)
Height Z-score −0.13±1.25 0.34±1.17 <0.05
−0.13 (−3.86–3.15) 0.25 (−2.44–3.2)
BMI Z-score 0.47±1.02 −0.05±1.02 <0.01
0.34 (−2.8–3.15) −0.18 (−1.58–3.3)
Overweight and obese, n (%) 28.57% 12.5%
Short stature, n (%) 18.63% 8.57%
Creatinine (mg/dl) 0.47 (0.2–0.9) 0.45 (0.3–0.95) NS
0.43±0.21 0.42±0.27
Albumin (g/dL) 4.21±1.27 4.02±2.13 NS
4.43 (3.8–5.1) 4.21 (2.8–4.5)
Protein/creatinine ratio 0.13±0.03 0.37±0.04 <0.05
0.15 (0.0–0.2) 0.45 (0.0–0.65)
RANKL (pmol/l) 0.36±0.33 0.25±0.28 <0.05
0.21 (0.01–1.36) 0.15 (0–1.42)
OPG (pmol/l) 3.79±0.99 4.33±1.36 <0.05
3.76 (1.01–7.25) 3.92 (2.39–10.23)
RANKL/OPG 0.11±0.12 0.06±0.08 <0.01
0.06 (0.002–0.71) 0.04 (0–0.37)
Table 1 Anthropometric,
clinical and metabolic charac-
teristics of subjects entered the
study
BMI, Body mass index;
RANKL, receptor activator of
NF-kB ligand; OPG, osteopro-
tegerin; NS, not significant
All values are given as the
mean ± standard deviation (SD)
and as the median and range (in
parenthesis), unless otherwise
noted
Variable La (n=50) Ha (n=40) p
Age at diagnosis (years) 5.13±4.21 5.31±4.53 NS
3.95 (1–17) 3 (0.5–15)
Interval since diagnosis (years) 2.94±3.61 7.82±4.26 <0.01
2.05 (0–16) 7.5 (0.5–16)
Number of NS relapses 3.14±2.29 8.28±2.39 <0.01
2 (1–9) 10 (1–15)
On GCS at visit, n (%) 17/50 (34%) 24/40 (60%)
Cumulative dose of GCS (g/kg) 0.36±0.32 1.82±0.67 <0.01
0.26 (0.12–0.99) 1.79 (1–3.78)
RANKL (pmol/l) 0.39±0.23 0.18±0.15 <0.01
0.46 (0.02–1.36) 0.19 (0.01–1.25)
OPG (pmol/l) 3.37±1.12 3.69±0.98 NS
3.72 (1.00–7.24) 3.77 (2.19–6.34)
RANKL/OPG 0.12±0.09 0.04±0.12 <0.01
0.14 (0.01–0.71) 0.05 (0.002–0.37)
Table 2 Clinical and metabolic







Continuous data are presented as
the mean ± SD and as
the median and range (in
parenthesis); categorical data are
presented as n and the
percentage (in parenthesis)
a L = low CGCS of <1 g/kg body
weight (BW); H = high CGCS
of ≥1 g/kg BW
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(3.56 pmol/l, 1.01–7.24 pmol/l) than that in the GCS (−)
group (3.99 pmol/l, 2.19–6.34 pmol/l) (p<0.01).
Logistic regression analysis was performed to evaluate
the risk factors. The incidence of increased serum RANKL
and RANKL/OPG ratio and decreased serum OPG was not
significantly associated with the variables sex (female), age
>10 years, Tanner stage (5th), height <3 centile, overweight
>90 centile, and age at onset >8 years.
Multivariate logistic regression analysis (data not shown)
of those clinical factors that might predict an increase in the
serum RANKL/OPG ratio in nephrotic patients identified
number of relapses >10 (OR 2.76, 95% CI 1.07–7.13; p<
0.05) and cumulative steroid dose >1 g/kg BW (OR 2.28,
95% CI 0.89–5.87 (p<0.05). The associations with serum
RANKL did not achieve statistical significance (p>0.05).
We also showed that the serum RANKL concentration
and RANKL/OPG ratio in the INS children were
significantly and positively correlated with GCS (in both
cases r=0.33, p<0.05). Each gram of CGCS used in the
therapy resulted in an increase in the RANKL serum
concentration about 0.13 pmol/l and in the RANKL/OPG
ratio of 0.05 (Fig. 2).
Using linear regression, we assessed whether the
decrease in height and increased BMI had an influence on
the association between the CGCS and serum RANKL and
RANKL/OPG ratio. This analysis revealed that the addition
of height <3 centile or BMI >90 centile increased the
association between these parameters.
The effect of an alternative treatment in NS children was
also analyzed. The children included to this study were not
receiving any other immunosuppressant drugs at the moment
of examination. However, 33 of the 90 NS children included
in our study had been treated with CSA in the past, which is
why we assessed the risk of increased serum RANKL
concentrations (above the median value of the NS group)
and decreased serum OPG concentrations (below the median
value of the NS group). We found that the OR of an increased
concentration of RANKL in patients treated with CSA was
1.83 (95% CI 0.77–4.34), and the relative risk of an increased
serum RANKL concentration in NS children treated with
CSA was 1.33 (0.8–1.9). Consequently, treatment with CSA
did not influence the serum OPG level.
The most important focus of our study was to analyze the
association between the examined parameters and the BMD in
NS children. Unfortunately, in our analysis, we were able to
assess the BMD in only 24/40 children treated with high doses
of GCS. The median BMD Z-score in this group was −0.79
(range −3.87–0.49). We confirmed GIOP in only two of 24
children, but there was a low normal Z-score BMD in 45.8%.
The OR of an increased concentration of RANKL in patients
with a low normal Z-score was 6 (95% CI 1.08–33.3).
We found a statistically significant correlation between
the BMD Z-score and serum RANKL (r= −0.44, p<0.05).
There was no correlation between the BMD Z-score and
serum OPG level (Fig. 3).
Discussion
To the best of our knowledge, our study is the first to
demonstrate the influence of the total cumulative dose of
GCS on serum RANKL and OPG concentrations and also
on the RANKL/OPG ratio in children and adolescents
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Fig. 2 Correlation between cumulative glucocorticoid dose (CGCS)
and serum concentration of RANKL and RANKL/OPG ratio
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treated with GCS due to steroid-sensitive or steroid
dependent NS and to compare the data to those obtained
from concurrent reference subjects (controls).
Our results show that in our study cohort, the circulating
OPG level was reduced and circulating RANKL level was
increased in INS patients compared to those of a reference
group. The most significant difference was found for the
RANKL/OPG ratio. The RANKL-to-OPG balance is of
critical importance for bone remodeling and the preservation
of bonemass.We confirmed that osteoclast activity is likely to
depend on the relative balance of RANKL and OPG, which is
why it has been suggested that the RANKL-to-OPG ratio in
serum—rather than individual protein concentrations—is the
critical factor for determining osteoclastic activation at the
bone level [6]. Alternation in this ratio has been confirmed in
several bone loss-associated diseases [18]. In our study, the
RANKL/OPG ratio was twofold higher in INS patients than
in the patients of the reference group. Conversely, Ozkaya et
al. found an increased OPG/RANKL ratio in children with
chronic renal failure, which may represent, as suggested by
the authors, a compensatory mechanism to the negative
balance of bone remodeling in this disease [19].
The relationship between OPG and other markers of
bone metabolism in patients with chronic glomerulonephri-
tis treated with GCS was assessed by Sasaki et al. [20].
These authors observed a significant reduction in serum
OPG immediately after starting the GCS treatment. This
lack of a progressive decrease in serum OPG levels at
consecutive examinations 1, 3, and 6 months post-treatment
initiation could be due in part to the reduction in GCS dose.
However, the limitation of that study was related to the low
number of patients with a different original diagnosis.
Freundlich et al. [21] observed an up-regulation of
RANKL in normal osteoblasts incubated with sera of NS
children in relapse and normal expression in those
incubated with sera of NS children in remission; this result
suggests that changes in RANKL expression in NS children
are transient and reversible. The study of Faienza et al. [22]
showed a down-regulation of OPG and over-expression of
RANKL in T-cells from patients with a 21-hydroxylase
deficiency who were treated with GCS, compared with
controls. Similarly increased concentrations of RANKL and
decreased concentrations of OPG were found in the serum
of these patients.
Opinions on BMD in INS children treated with GCS are
equivocal. GCS have been reported to have much less of an
adverse effect on bone in patients with non-inflammatory
conditions than in the presence of inflammation [3, 4, 23].
The results of recent animal studies demonstrate that GCS
administration during growth can result in decreased bone
formation, decreased bone resorption, and a reduction in
age-dependent increases in trabecular bone mineral and
trabecular thickness [24, 25]. However, it is likely that the
underlying disease also carries the risk of osteoporosis. In
this setting, the independent effects of GCS on bone
turnover and bone structure are not easily apparent.
Leonard et al. [3] found a significant reduction in BMC in
patients with Crohn’s disease, but a normal spine or even
greater whole-body BMC in patients with steroid-sensitive
NS. The explanation for this difference may be the
detrimental effects on bone metabolism of inflammatory
cytokines such as TNF alpha and interleukin-1 and -6,
which are similar to GCS effects [26]. Childhood NS, in
contrast to other systemic diseases, is associated with
transient increases in cytokine levels, which resolves with
GCS treatment and disease remission. Burnham et al. [23]
suggested that inflammatory cytokines induced deleterious
changes in osteoblast GCS metabolism.
We confirmed a significant positive correlation between
CGCS and an increased serum RANKL concentration and
increased RANKL/OPG ratio. The correlation with serum
OPG was negative, but not statistically significant. A
possible explanation for this result is the fact that GCS
decrease the OPG level only during the therapy itself. We
suggest that an increase in serum OPG levels post-GCS
treatment could possibly compensate for an increase in
bone resorption. Similarly, the OPG level was not correlated
to the cumulative or current dose of glucocorticoids in patients
after cardiac transplant [27]. The study of Asanuma et al.
[28] even found a positive correlation between OPG and
cumulative dose of steroids.
We found a statistically significant higher serum
RANKL concentration and higher RANKL/OPG ratio in
the group of children treated with a high dose of GCS in
comparison to the group of children who had minimal
exposure to GCS. In a further analysis, we found a higher
serum level of RANKL and lower level of OPG in children
receiving GCS; however, the difference between the levels of
OPG was highly statistically significant and that between the
levels of RANKL was borderline statistically significant.
Spearman correlation: r = -0.4416, p<0.05





















Fig. 3 Correlation between the bone mineral density (BMD) Z-score
and serum RANKL concentration in nephrotic syndrome (NS)
children
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Freundlich et al. [21] reported that changes in osteoblastic
RANKL expression were not influenced by the concurrent
administration of steroids. Further analysis according to the
actual dose or number of days of therapy goes beyond this
paper.
High CGSC was independently associated with an
increased serum RANKL concentration and an increased
RANKL/OPG ratio, even when controlled for BMI Z-score.
It is well known fact that complex hormonal changes occur in
obesity, such as elevations in the concentration of insulin, sex
hormone, and leptin, and that this may increase osteoblast
activity and decrease osteoclast activity [29, 30].
There is a growing body of literature suggesting the role of
factors other than GCS drugs in the pathogenesis of
iathrogenic osteoporosis. CSA has been confirmed to be
involved in the pathogenesis of post-transplant osteoporosis
and vascular disease [31]. CSA, similar to GCS, has been
shown to inhibit OPG and stimulate RANKL in cell cultures
[32]. However, the results from clinical studies are equivocal,
probably because in most protocols the CSA is used together
with GCS, and the authors were consequently not able to
exclude other important confounders, such as hormonal
disturbances, vascular changes in the course of chronic
kidney disease, low BMI, or decreased physical activity. We
also were only able to present the increased relative risk of
higher serum RANKL in NS children treated with CSA.
However, our findings were not conclusive enough to
suggest an influence of CSA treatment on serum RANKL
because the samples were obtained from patients at different
time-points during their treatment regimen. Further studies
are necessary to confirm this observation.
Another issue is the correlation between the parameters
analyzed and the BMD. Results from cross-sectional
studies in humans vary from no association between
BMD and OPG [33, 34] to a decrease in BMD with
increasing OPG [35]. Similarly, for RANKL, a few studies
have shown no association between RANKL and BMD
[36], while others have shown a decrease in BMD with
increasing RANKL levels [37]. The possible consequences
of corticosteroid therapy on BMD in NS children have also
been contradictory, resulting in low [38] or normal [4, 39]
BMD values. The reason for these differences may be that
the DXA examination was conducted in an optional time-
frame, with no relation to disease activity and steroid
administration. In our analysis, we assessed the BMC only
in 24/40 children treated with high-dose GCS. In accor-
dance with the new official position of the International
Society for Clinical Densitometry on DXA evaluation in
children and adolescents [40], we confirmed GIOP only in
two of 24 children. We noted an inverse correlation with the
prevailing RANKL levels. Longer follow-up studies with a
larger number of patients will be needed to evaluate the
impact of RANKL levels on the reduction in BMD.
In conclusion, we observed that: (1) INS children treated
with GCS had an increased serum RANKL level, increased
RANKL/OPG ratio, and decreased serum OPG level; (2)
there was a significant positive correlation between the
cumulative dose of GCS and the serum RANKL and
RANKL/OPG ratio, but not with the serum OPG level; (3)
concurrent GCS treatment increased the serum RANKL
level and decreased the serum OPG level; (4) serum
RANKL level, but not OPG level, correlated with the
BMD Z-score, but further studies are necessary to confirm
this observation.
Our study should be interpreted within the context of its
limitations. First, we were not able to obtain sufficient
samples from children suffering their first attack of INS
before they had received GCS treatment to assess the
influence of proinflammatory cytokines on serum RANKL
and OPG levels. In a furture study, we also plan to monitor
the level of both cytokines in the relapse of NS and then in
the remission of proteinuria. Secondly, serum RANKL and
OPG may not reflect the levels and activity of these
cytokines in the bone microenvironment, since a small
amount of locally acting cytokines leak to systemic
circulation [41], and a part of serum OPG and RANKL
may also originate from non-skeletal sources. Thirdly, the
commercially available assays were designed to detect all
forms of OPG (monomer, dimer, RANKL/OPG complex)
and not exclusively the dimeric form, which is thought to
be the biologically active form [41]. Fourthly, serum
RANKL constitutes only a small part of total RANKL, as
the majority is cell bound and thus not detectable in the
circulation. However, a more accurate method that assesses
cell-surface production of RANKL is very impractical in
humans [41] because it requires bone biopsy.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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